The company noted that Ivany was formerly president, CEO and director of AgraFlora Organics International Inc.
Inc () (OTCMKTS:CANVF) has announced the appointment of Derek Ivany as chairman of its advisory board where he will be focusing efforts on expanding the brand across Europe and South America through M&A and other value enhancing tactical corporate maneuvers.
The leading global markets cannabis brand for empowering the medical, recreational and CPG cannabis industry worldwide noted that Ivany was formerly president, CEO and Director of (), a growth-oriented and diversified company focused on the international cannabis industry.
READ: EuroLife Brands focuses on pet, human consumables market as part of its global cannabis brand strategy
It pointed out that he helped propel AgraFlora from an under $2 million in market capitalization to over $250 million at its zenith, along with undertaking multiple significant capital raises and generating significant investor liquidity whilst at the helm of AgraFlora.
In a statement, Steve Loutskou, chief operating officer, Global Markets, said: “We are thrilled to have Derek join EuroLife as a strategic advisor, bringing with him a wealth of expertise and experience in the global cannabis sector along with a proven track record of success in helping companies like ours meet and exceed stated corporate objectives.”
“Derek will be further focused on expanding our brand across Europe through various means, including strategic mergers and acquisitions, with a view to maximizing stakeholder benefit,” he added.
Alongside Loutskou, the company said Ivany will be focused on ramping up the firm’s aggressive expansion into Europe, initially leveraging the launch of EuroLife Marketplace; a digital CPG platform focused on CBD products backed by unbiased and evidence-based digital cannabis education from the Company’s Cannvas.Me platform.
Ivany commented: “The EuroLife team has built a tremendous platform from which to build upon and it is ripe for monetization.
“The opportunities that lay ahead for the advancement of the business are truly compelling and, as such, I am eager and committed to dedicating significant efforts towards assisting EuroLife in capitalizing on this next phase of global cannabis normalization.”
The company also announced that it has granted incentive stock options to purchase a total of 9,755,000 common shares at an exercise price of $0.11 per share for a period of two years to certain directors, officers and consultants in accordance with the provisions of its stock option plan.
Contact the author at [email protected]
